Shiqi Wu

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Qingyong Ma · 3 shared papers, 2020–2024 · strength 0.51
   • Paper Corrigendum to "2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensiti… DOI 10.1016/j.canlet.2023.216602↗
   • Paper Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensit… DOI 10.1016/j.canlet.2022.215913↗
   • Paper 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inh… DOI 10.1016/j.canlet.2019.11.041↗
2. Weikun Qian · 3 shared papers, 2020–2024 · strength 0.51
   • Paper Corrigendum to "2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensiti… DOI 10.1016/j.canlet.2023.216602↗
   • Paper Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensit… DOI 10.1016/j.canlet.2022.215913↗
   • Paper 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inh… DOI 10.1016/j.canlet.2019.11.041↗
3. Yangyang Yue · 3 shared papers, 2020–2024 · strength 0.51
   • Paper Corrigendum to "2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensiti… DOI 10.1016/j.canlet.2023.216602↗
   • Paper Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensit… DOI 10.1016/j.canlet.2022.215913↗
   • Paper 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inh… DOI 10.1016/j.canlet.2019.11.041↗
4. Zheng Wang · 3 shared papers, 2020–2024 · strength 0.51
   • Paper Corrigendum to "2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensiti… DOI 10.1016/j.canlet.2023.216602↗
   • Paper Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensit… DOI 10.1016/j.canlet.2022.215913↗
   • Paper 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inh… DOI 10.1016/j.canlet.2019.11.041↗
5. Yungen Xu · 3 shared papers, 2021–2022 · strength 0.44
   • Paper FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signali… DOI 10.1016/j.phrs.2021.106040↗
   • Paper Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. DOI 10.1016/j.ejmech.2022.114116↗
   • Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535↗
6. Shihui Huang · 3 shared papers, 2021–2022 · strength 0.44
   • Paper FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signali… DOI 10.1016/j.phrs.2021.106040↗
   • Paper Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. DOI 10.1016/j.ejmech.2022.114116↗
   • Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535↗
7. Jie Li · 2 shared papers, 2022–2024 · strength 0.39
   • Paper Corrigendum to "2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensiti… DOI 10.1016/j.canlet.2023.216602↗
   • Paper Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensit… DOI 10.1016/j.canlet.2022.215913↗
8. Qin Sun · 2 shared papers, 2021–2022 · strength 0.27
   • Paper Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. DOI 10.1016/j.ejmech.2022.114116↗
   • Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535↗
9. Shuping Wang · 1 shared paper, 2022 · strength 0.17
   • Paper FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signali… DOI 10.1016/j.phrs.2021.106040↗
10. Zheng Wu · 1 shared paper, 2022 · strength 0.16
    • Paper Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensit… DOI 10.1016/j.canlet.2022.215913↗
11. Shuping Wang · 1 shared paper, 2022 · strength 0.15
    • Paper Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. DOI 10.1016/j.ejmech.2022.114116↗
12. Yu Li · 1 shared paper, 2021 · strength 0.12
    • Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535↗
13. Shu-Ping Wang · 1 shared paper, 2021 · strength 0.12
    • Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535↗
14. Zheng Wu · 1 shared paper, 2020 · strength 0.12
    • Paper 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inh… DOI 10.1016/j.canlet.2019.11.041↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.